25
Apr
While we differentiated between initial and recurrent disease, our survey did not specify the interval at which flares occurred. with cyclophosphamide and rituximab varied significantly among the experts. The majority agreed that AEs related to fertility, infections, and serious infusion reactions were extremely or very important to disclose. Less than half of the experts surveyed endorsed disclosing the risks of progressive multifocal leukoencephalopathy, hepatitis reactivation, or zoster. For patients with newly-diagnosed AAV, the majority of experts preferred IV cyclophosphamide for older adults and rituximab for younger women with newly-diagnosed AAV. For patients with recurrent disease SB 271046 Hydrochloride who had…